2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome: Executive Summary
-
- Mary-Ann Fitzcharles
- Division of Rheumatology, McGill University, Canada
-
- Peter A Ste-Marie
- Alan Edwards Pain Management Unit, McGill University Health Centre, Canada
-
- Don L Goldenberg
- Division of Rheumatology, Tufts University School of Medicine, Boston, Massachusetts, USA
-
- John X Pereira
- Department of Family Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
-
- Susan Abbey
- Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
-
- Manon Choinière
- Centre de la recherche du Centre hospitalier de l’Université de Montréal, Department of Anesthesiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
-
- Gordon Ko
- Division of Physiatry, University of Toronto, Toronto, Canada
-
- Dwight E Moulin
- Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario, London, Ontario, Canada
-
- Pantelis Panopalis
- Division of Rheumatology, McGill University, Canada
-
- Johanne Proulx
- Patient representative, Canada
-
- Yoram Shir
- Alan Edwards Pain Management Unit, McGill University Health Centre, Canada
Description
<jats:p>BACKGROUND: Recent neurophysiological evidence attests to the validity of fibromyalgia (FM), a chronic pain condition that affects >2% of the population.</jats:p><jats:p>OBJECTIVES: To present the evidence-based guidelines for the diagnosis, management and patient trajectory of individuals with FM.</jats:p><jats:p>METHODS: A needs assessment following consultation with diverse health care professionals identified questions pertinent to various aspects of FM. A literature search identified the evidence available to address these questions; evidence was graded according to the standards of the Oxford Centre for Evidence-Based Medicine. Drafted recommendations were appraised by an advisory panel to reflect meaningful clinical practice.</jats:p><jats:p>RESULTS: The present recommendations incorporate the new clinical concepts of FM as a clinical construct without any defining physical abnormality or biological marker, characterized by fluctuating, diffuse body pain and the frequent symptoms of sleep disturbance, fatigue, mood and cognitive changes. In the absence of a defining cause or cure, treatment objectives should be patient-tailored and symptom-based, aimed at reducing global complaints and enhancing function. Healthy lifestyle practices with active patient participation in health care forms the cornerstone of care. Multimodal management may include nonpharmacological and pharmacological strategies, although it must be acknowledged that pharmacological treatments provide only modest benefit. Maintenance of function and retention in the workforce is encouraged.</jats:p><jats:p>CONCLUSIONS: The new Canadian guidelines for the treatment of FM should provide health professionals with confidence in the complete care of these patients and improve clinical outcomes.</jats:p>
Journal
-
- Pain Research and Management
-
Pain Research and Management 18 (3), 119-126, 2013
Hindawi Limited
- Tweet
Details 詳細情報について
-
- CRID
- 1362544419088555264
-
- ISSN
- 12036765
-
- Data Source
-
- Crossref